Please login to the form below

Not currently logged in
Email:
Password:

Yescarta

This page shows the latest Yescarta news and features for those working in and with pharma, biotech and healthcare.

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

Incyte signs lymphoma deal worth up to $1.1bn with MorphoSys

If approved, tafasitamab will go on to compete with existing cancer drugs including CAR-T therapies like Novartis’  Kymriah (tisagenlecleucel) and Gilead’s  Yescarta (axicabtagene ciloleucel).

Latest news

More from news
Approximately 11 fully matching, plus 46 partially matching documents found.

Latest Intelligence

More from intelligence
Approximately 0 fully matching, plus 10 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete Medical Communications (CMC)

CMC is a leading global agency dedicated to healthcare communications across the lifecycle. We combine scientific acumen, excellence in delivery...

Latest intelligence

How do companies prepare for reimbursement?
Valid Insight explore how to optimise your market access strategy during new product development, how to address payer concerns and prepare for reimbursement....
EHR clinical trials
Integrating electronic health records into clinical trials
How organisations are working to realise the research potential of EHRs...
Mike Elliott Gilead
Keeping up the fight against HIV and using the lessons to tackle other threats
Danny Buckland interviews Gilead’s Mike Elliott...

Infographics